{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:49:29Z","timestamp":1792007369000,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jtct.2025.12.943","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:14:50Z","timestamp":1765815290000},"page":"565-574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pretransplantation Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia Patients: A Real-World Analysis from the Cooperative Transplant Study Group"],"prefix":"10.1016","volume":"32","author":[{"given":"Christina","family":"Rautenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9331-5145","authenticated-orcid":false,"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2359-131X","authenticated-orcid":false,"given":"Gesine","family":"Bug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5543-0257","authenticated-orcid":false,"given":"Udo","family":"Holtick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Jennrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Mohring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Tischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Fraccaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1755-9583","authenticated-orcid":false,"given":"Christoph","family":"Schliemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6080-6175","authenticated-orcid":false,"given":"Laura K.","family":"Schmalbrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5890-5510","authenticated-orcid":false,"given":"Lars","family":"Bullinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1607-0160","authenticated-orcid":false,"given":"Judith","family":"Metzdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4028-5357","authenticated-orcid":false,"given":"Krischan","family":"Braitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Verbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6276-8002","authenticated-orcid":false,"given":"Katharina","family":"G\u00f6tze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6207-0237","authenticated-orcid":false,"given":"Fabian","family":"Acker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Christian","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jtct.2025.12.943_bib0001","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.943_bib0002","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"issue":"18","key":"10.1016\/j.jtct.2025.12.943_bib0003","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2013.52.8562","article-title":"International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia","volume":"32","author":"Roboz","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.943_bib0004","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.2019001982","article-title":"How I treat relapsed or refractory AML","volume":"136","author":"DeWolf","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.943_bib0005","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/bloodadvances.2024013086","article-title":"Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed\/refractory AML","volume":"9","author":"Unglaub","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.943_bib0006","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/cancers14010022","article-title":"Venetoclax in relapsed\/refractory acute myeloid leukemia: are supporting evidences enough?","volume":"14","author":"Brancati","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.943_bib0007","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1097\/HS9.0000000000000549","article-title":"Safety and efficacy: clinical experience of venetoclax in combination with hypomethylating agents in both newly diagnosed and relapsed\/refractory advanced myeloid malignancies","volume":"5","author":"Feld","year":"2021","journal-title":"Hemasphere"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.943_bib0008","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"103","author":"Aldoss","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.943_bib0009","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3390\/cancers14082025","article-title":"Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients","volume":"14","author":"Garciaz","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.943_bib0010","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.3390\/cancers14071734","article-title":"Use of venetoclax in patients with relapsed or refractory acute myeloid leukemia: the PETHEMA registry experience","volume":"14","author":"Labrador","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.943_bib0011","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.jtct.2025.12.943_bib0012","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jtct.2025.12.943_bib0013","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jtct.2025.12.943_bib0014","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2025.12.943_bib0015","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"10.1016\/j.jtct.2025.12.943_bib0016","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.2006.09.7865","article-title":"Comorbidity and disease status\u2013based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation","volume":"25","author":"Sorror","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.12.943_bib0017","doi-asserted-by":"crossref","unstructured":"Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295-304.","DOI":"10.1097\/00007890-197410000-00001"},{"issue":"12","key":"10.1016\/j.jtct.2025.12.943_bib0018","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.943_bib0019","doi-asserted-by":"crossref","first-page":"694.e1","DOI":"10.1016\/j.jtct.2022.07.022","article-title":"Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received venetoclax + azacitidine versus intensive chemotherapy","volume":"28","author":"Winters","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.943_bib0020","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41409-021-01476-7","article-title":"Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60","volume":"57","author":"Pollyea","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.943_bib0021","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3390\/cancers16061082","article-title":"Venetoclax plus azacitidine as a bridge treatment to allogeneic stem cell transplantation in unfit patients with acute myeloid leukemia","volume":"16","author":"Chen","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"14","key":"10.1016\/j.jtct.2025.12.943_bib0022","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1080\/10428194.2021.1966788","article-title":"Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant","volume":"62","author":"Bewersdorf","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.jtct.2025.12.943_bib0023","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/j.bbmt.2020.08.027","article-title":"Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myelogenous leukemia","volume":"26","author":"Sandhu","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"30","key":"10.1016\/j.jtct.2025.12.943_bib0024","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1200\/JCO.20.02724","article-title":"Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo study)","volume":"39","author":"Kr\u00f6ger","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2025.12.943_bib0025","doi-asserted-by":"crossref","first-page":"e830","DOI":"10.1016\/S2352-3026(24)00241-2","article-title":"Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol"},{"issue":"26","key":"10.1016\/j.jtct.2025.12.943_bib0026","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.943_bib0027","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.943_bib0028","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/bloodadvances.2024014279","article-title":"Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS","volume":"9","author":"Cluzeau","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.943_bib0029","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41408-025-01274-0","article-title":"Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia \u2013 long-term follow-up with focus on younger patients","volume":"15","author":"Rautenberg","year":"2025","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.jtct.2025.12.943_bib0030","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(23)00273-9","article-title":"10-day decitabine versus 3\u2008+\u20087 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial","volume":"10","author":"L\u00fcbbert","year":"2023","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.943_bib0031","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00277-018-3304-y","article-title":"Salvage regimens using conventional chemotherapy agents for relapsed\/refractory adult AML patients: a systematic literature review","volume":"97","author":"Meg\u00edas-Vericat","year":"2018","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.943_bib0032","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1182\/blood.V69.3.744.744","article-title":"High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia","volume":"69","author":"Hiddemann","year":"1987","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.943_bib0033","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/10428199309147373","article-title":"Bisantrene in relapsed and refractory acute myelogenous leukemia","volume":"9","author":"Spadea","year":"1993","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.943_bib0034","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2352-3026(24)00065-6","article-title":"Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial","volume":"11","author":"Stelljes","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2025.12.943_bib0035","first-page":"72","article-title":"Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed\/refractory acute myeloid leukemia","volume":"109","author":"Shahswar","year":"2024","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.jtct.2025.12.943_bib0036","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.jtct.2025.12.943_bib0037","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3 -mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.943_bib0038","doi-asserted-by":"crossref","first-page":"265.e1","DOI":"10.1016\/j.jtct.2022.12.006","article-title":"Outcomes in patients with FLT3-mutated relapsed\/refractory acute myelogenous leukemia who underwent transplantation in the phase 3 ADMIRAL trial of gilteritinib versus salvage chemotherapy","volume":"29","author":"Perl","year":"2023","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725026016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725026016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:08:45Z","timestamp":1780312125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725026016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666636725026016"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.943","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pretransplantation Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia Patients: A Real-World Analysis from the Cooperative Transplant Study Group","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}